Back to Search Start Over

Depression, Suicidal Ideation, and Consumption of Psychotropic Drugs During Lockdown by COVID-19 According to Gender and Age.

Authors :
Villanueva-Blasco VJ
Villanueva-Silvestre V
Vázquez-Martínez A
de Vicente LP
Pérez-Gálvez B
Source :
International journal of mental health and addiction [Int J Ment Health Addict] 2022 Nov 22, pp. 1-17. Date of Electronic Publication: 2022 Nov 22.
Publication Year :
2022
Publisher :
Ahead of Print

Abstract

The objective was to analyze the relationship between depression and suicidal ideation and psychotropic drugs use during COVID-19 lockdown in adult population considering gender and age. The method used is a descriptive and non-probabilistic study, with a convenience sampling of 3780 participants (70.1% female), aged 18-64 years (M = 37.8). 18.3% participants presented depression and 5.1% exhibited suicidal ideation. The depression rate for female was double (21.4%) than male and 5 times higher (30.2%) for the youngest participants (18-24 years old) compared to oldest (55-64 years old), being this rate triple in suicidal ideation (9%). Depression correlated positively with tranquilizers and sleeping pills' consumption; and suicidal ideation did so with tranquilizers and sedatives. The rate of tranquilizer users was 8 times higher for severe depression compared to those who did not present depression, 5 times higher for sleeping pills, and 6 times higher for sedatives. The rate of tranquilizer users exhibiting suicidal ideation was more than triple than those who did not present suicidal ideation, between 3 and 4 times higher for sleeping pills, and almost 7 times higher for sedatives. The higher the level of depression and suicidal ideation during lockdown, the greater the consumption of psychotropic drugs. The consumption of psychotropic drugs should be monitored in people with depression and suicidal ideation during periods of crisis.<br />Competing Interests: Conflicts of InterestThe authors declare no competing interests.<br /> (© The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature 2022, Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.)

Details

Language :
English
ISSN :
1557-1874
Database :
MEDLINE
Journal :
International journal of mental health and addiction
Publication Type :
Academic Journal
Accession number :
36465995
Full Text :
https://doi.org/10.1007/s11469-022-00962-3